Literature DB >> 17683066

STAT1 expression is not required for polyp formation in Min mice.

Forrester J Liddle1, David A Frank.   

Abstract

Recent studies have suggested the importance of interleukin (IL)-6 signaling in the development of colon cancer. Expression of IL-6 and the IL-6 receptor have been found to be elevated in colorectal carcinoma tissue, and IL-6 has been found to be critical for tumor formation in mouse models of colon cancer. IL-6 mediated activation of the transcription factor STAT1 has been shown to be important in protection of colorectal carcinoma cells from apoptotic signals. To test the hypothesis that the IL-6-STAT1 axis plays a role in early stages of colon cancer development, we examined the role of this pathway in the mouse multiple intestinal neoplasia (Min) model of intestinal tumorigenesis. Due to low fecundity, we were unable to generate Min mice lacking expression of IL-6. We then focused on the role of STAT1 in intestinal polyp formation in these animals. Min mice lacking STAT1 or heterozygous for STAT1 developed polyps in similar numbers as those expressing STAT1. Furthermore, the anatomic distribution and histological characteristics of these polyps did not vary among these populations. These results indicate that STAT1 does not play a role in the pathogenesis of the Min model for colon cancer. However, they do not rule out the possibility that STAT1 plays a role in other stages of colon cancer development. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17683066     DOI: 10.1002/mc.20371

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

1.  Mthfd1 is a modifier of chemically induced intestinal carcinogenesis.

Authors:  Amanda J MacFarlane; Cheryll A Perry; Michael F McEntee; David M Lin; Patrick J Stover
Journal:  Carcinogenesis       Date:  2010-12-14       Impact factor: 4.944

2.  Inactivation of the vitamin D receptor in APC(min/+) mice reveals a critical role for the vitamin D receptor in intestinal tumor growth.

Authors:  Wei Zheng; Kari E Wong; Zhongyi Zhang; Urzsula Dougherty; Reba Mustafi; Juan Kong; Dilip K Deb; Huachuan Zheng; Marc Bissonnette; Yan Chun Li
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

3.  IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer.

Authors:  Mizuho Sakahara; Takuya Okamoto; Jun Oyanagi; Hiroshi Takano; Yasuko Natsume; Hitomi Yamanaka; Daisuke Kusama; Mishio Fusejima; Norio Tanaka; Seiich Mori; Hiroshi Kawachi; Masashi Ueno; Yoshiharu Sakai; Tetsuo Noda; Satoshi Nagayama; Ryoji Yao
Journal:  Cancer Sci       Date:  2019-03-22       Impact factor: 6.716

4.  IDO1+ Paneth cells promote immune escape of colorectal cancer.

Authors:  Sandra Pflügler; Jasmin Svinka; Irene Scharf; Ilija Crncec; Martin Filipits; Pornpimol Charoentong; Markus Tschurtschenthaler; Lukas Kenner; Monira Awad; Judith Stift; Marina Schernthanner; Romana Bischl; Dietmar Herndler-Brandstetter; Elisabeth Glitzner; Herwig P Moll; Emilio Casanova; Gerald Timelthaler; Maria Sibilia; Michael Gnant; Sigurd Lax; Josef Thaler; Mathias Müller; Birgit Strobl; Thomas Mohr; Arthur Kaser; Zlatko Trajanoski; Gerwin Heller; Robert Eferl
Journal:  Commun Biol       Date:  2020-05-22

Review 5.  Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer.

Authors:  Sebastian Zundler; Markus F Neurath
Journal:  Vaccines (Basel)       Date:  2016-02-29

6.  STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer.

Authors:  Ilija Crnčec; Madhura Modak; Claire Gordziel; Jasmin Svinka; Irene Scharf; Stefan Moritsch; Paulina Pathria; Michaela Schlederer; Lukas Kenner; Gerald Timelthaler; Mathias Müller; Birgit Strobl; Emilio Casanova; Editha Bayer; Thomas Mohr; Johannes Stöckl; Karlheinz Friedrich; Robert Eferl
Journal:  Mol Oncol       Date:  2018-02-20       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.